Black Diamond Therapeutics (NASDAQ:BDTX – Get Free Report) and Cardio Diagnostics (NASDAQ:CDIO – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their risk, analyst recommendations, valuation, institutional ownership, earnings, profitability and dividends.
Profitability
This table compares Black Diamond Therapeutics and Cardio Diagnostics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Black Diamond Therapeutics | N/A | -32.10% | -25.21% |
| Cardio Diagnostics | -43,133.33% | -82.28% | -76.03% |
Valuation & Earnings
This table compares Black Diamond Therapeutics and Cardio Diagnostics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Black Diamond Therapeutics | N/A | N/A | $22.37 million | ($0.75) | -2.97 |
| Cardio Diagnostics | $10,000.00 | 547.60 | -$6.50 million | ($2.92) | -0.63 |
Black Diamond Therapeutics has higher earnings, but lower revenue than Cardio Diagnostics. Black Diamond Therapeutics is trading at a lower price-to-earnings ratio than Cardio Diagnostics, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of current recommendations and price targets for Black Diamond Therapeutics and Cardio Diagnostics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Black Diamond Therapeutics | 1 | 2 | 8 | 0 | 2.64 |
| Cardio Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
Black Diamond Therapeutics presently has a consensus target price of $9.80, indicating a potential upside of 339.46%. Given Black Diamond Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Black Diamond Therapeutics is more favorable than Cardio Diagnostics.
Insider & Institutional Ownership
95.5% of Black Diamond Therapeutics shares are owned by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are owned by institutional investors. 9.3% of Black Diamond Therapeutics shares are owned by company insiders. Comparatively, 9.0% of Cardio Diagnostics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Risk & Volatility
Black Diamond Therapeutics has a beta of 3.28, indicating that its share price is 228% more volatile than the S&P 500. Comparatively, Cardio Diagnostics has a beta of 2.27, indicating that its share price is 127% more volatile than the S&P 500.
Summary
Black Diamond Therapeutics beats Cardio Diagnostics on 11 of the 13 factors compared between the two stocks.
About Black Diamond Therapeutics
Black Diamond Therapeutics, Inc., a clinical-stage oncology medicine company, focuses on the discovery and development of MasterKey therapies for patients with genetically defined tumors. The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth factor receptor mutant non-small cell lung cancer, as well as phase 1 clinical trial to treat glioblastoma. It is also developing BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS, and BRAF alterations in solid tumors that is in phase 1 clinical trial. In addition, the company is developing BDTX-4876, a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4, which is in preclinical stage. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
About Cardio Diagnostics
Cardio Diagnostics Holdings, Inc. develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen CHD, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks; and PrecisionCHD, an integrated epigenetic-genetic blood test for the early detection of coronary heart disease. Cardio Diagnostics Holdings, Inc. was founded in 2017 and is headquartered in Chicago, Illinois.
Receive News & Ratings for Black Diamond Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Black Diamond Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
